Search - tctmd.com

Displaying 461 - 480 of 609

Sort: Relevancy | Date

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

薄帽纤维粥样瘤可能有助于解释为何糖尿病患者 PCI 结局较差

Todd Neale

July 06, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

News Daily News

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Todd Neale

July 06, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Yael L. Maxwell

June 29, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

研究显示糖尿病患者急性心梗后风险差异很大

L.A. McKeown

May 26, 2016

News Daily News

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Daily News

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Yael L. Maxwell

May 13, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Michael O'Riordan

April 25, 2016

Advertisement

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

薄帽纤维粥样瘤可能有助于解释为何糖尿病患者 PCI 结局较差

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

研究显示糖尿病患者急性心梗后风险差异很大

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content